Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Japan; Department of Surgical Oncology and Pediatric Surgery, Gifu University Graduate School of Medicine, Japan.
Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Japan.
Pancreatology. 2024 Nov;24(7):1174-1181. doi: 10.1016/j.pan.2024.10.003. Epub 2024 Oct 1.
The prognostic impact of additional resection based on intraoperative frozen section analysis (FSA) of the pancreatic transection margin in patients with pancreatic ductal adenocarcinoma (PDAC) is controversial. The purpose of this study was to evaluate the prognosis based on the results of the first FSA of the pancreatic transection margin (1st FSA) and the clinical significance of additional resection.
Patients who underwent pancreaticoduodenectomy for PDAC from 2000 to 2020 at a single center were included. Patients were divided into 3 groups based on the 1FSA. Survival and prognostic factors were analyzed according to the 1FSA.
A total of 311 patients were included in this study. The 1FSA was negative in 272 patients (1FSA-R0) and positive in 39 patients [carcinoma in situ (1FSA-CIS), 21 patients; invasive carcinoma (1FSA-IC), 18 patients]. Additional resections were performed on 37 patients [1FSA-CIS, 20 patients; 1FSA-IC, 17 patients], and R0 resection was achieved in 34 patients intraoperatively. Comparing median survival time to 1FSA-R0 (36.4 months), 1FSA-CIS was comparable (27.8 months, p = 0.276), although 1FSA-IC was significantly worse (18.8 months, p = 0.001). On multivariate analysis, 1FSA-IC was an independent prognostic factor (hazard ratio 2.68, 95 % confidence interval 1.16-6.17, p = 0.020).
1FSA-CIS and 1FSA-R0 had similar OS, implying that additional resection may be acceptable for 1FSA-CIS. 1FSA-IC was still an independent prognostic factor based on additional resection, and the prognostic significance of additional resection is uncertain for 1FSA-IC.
基于术中冷冻切片分析(FSA)对胰腺横断缘的评估,对胰腺导管腺癌(PDAC)患者进行额外切除的预后影响存在争议。本研究的目的是评估首次胰腺横断缘 FSA(1st FSA)的结果,并探讨额外切除的临床意义。
纳入 2000 年至 2020 年期间在单中心行胰十二指肠切除术治疗 PDAC 的患者。根据 1st FSA 将患者分为 3 组。根据 1st FSA 分析生存情况和预后因素。
本研究共纳入 311 例患者。272 例患者 1st FSA 为阴性(1st FSA-R0),39 例患者为阳性[原位癌(1st FSA-CIS),21 例;浸润性癌(1st FSA-IC),18 例]。对 37 例患者进行了额外切除[1st FSA-CIS,20 例;1st FSA-IC,17 例],术中均达到了 R0 切除。与 1st FSA-R0 的中位生存时间(36.4 个月)相比,1st FSA-CIS 相似(27.8 个月,p=0.276),但 1st FSA-IC 显著更差(18.8 个月,p=0.001)。多因素分析显示,1st FSA-IC 是独立的预后因素(风险比 2.68,95%置信区间 1.16-6.17,p=0.020)。
1st FSA-CIS 和 1st FSA-R0 的 OS 相似,提示对于 1st FSA-CIS,额外切除可能是可以接受的。基于额外切除,1st FSA-IC 仍然是独立的预后因素,而对于 1st FSA-IC,额外切除的预后意义尚不确定。